In contrast, GFAP displayed a more selective trajectory, with marked elevations primarily in individuals who later developed AD, while no significant associations were found with incident ALS or parkinsonian syndromes, suggesting astrocytic activation mainly in the pre-diagnostic phase of Alzheimer’s disease. This evidence concerns the gene GFAP and Alzheimer disease.